Free Trial

Qiagen (NYSE:QGEN) Receives Consensus Rating of "Moderate Buy" from Brokerages

Qiagen logo with Medical background

Qiagen (NYSE:QGEN - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the ten brokerages that are covering the stock, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $51.15.

A number of equities analysts have commented on the stock. Hsbc Global Res raised shares of Qiagen to a "hold" rating in a research note on Thursday, October 17th. HSBC cut Qiagen from a "buy" rating to a "hold" rating and set a $49.00 target price on the stock. in a research note on Thursday, October 17th. Finally, Jefferies Financial Group reaffirmed a "buy" rating and set a $54.00 price target (up previously from $42.00) on shares of Qiagen in a research note on Tuesday, December 10th.

Check Out Our Latest Research Report on QGEN

Institutional Investors Weigh In On Qiagen

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP increased its stake in Qiagen by 77.7% during the 3rd quarter. Wellington Management Group LLP now owns 21,250,943 shares of the company's stock valued at $963,386,000 after purchasing an additional 9,293,040 shares in the last quarter. Nuance Investments LLC boosted its holdings in Qiagen by 17.3% in the second quarter. Nuance Investments LLC now owns 5,271,494 shares of the company's stock worth $216,606,000 after purchasing an additional 778,005 shares during the last quarter. Earnest Partners LLC grew its position in Qiagen by 11.1% in the 2nd quarter. Earnest Partners LLC now owns 3,807,284 shares of the company's stock worth $156,441,000 after purchasing an additional 379,679 shares during the period. DekaBank Deutsche Girozentrale raised its stake in Qiagen by 12.2% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 3,248,354 shares of the company's stock valued at $133,292,000 after buying an additional 353,280 shares during the last quarter. Finally, Victory Capital Management Inc. lifted its holdings in shares of Qiagen by 62.6% during the 3rd quarter. Victory Capital Management Inc. now owns 2,574,705 shares of the company's stock valued at $117,329,000 after buying an additional 991,325 shares during the period. 70.00% of the stock is owned by hedge funds and other institutional investors.

Qiagen Price Performance

Qiagen stock traded down $0.56 during midday trading on Friday, hitting $45.40. 2,129,085 shares of the company's stock were exchanged, compared to its average volume of 790,870. The company has a market cap of $10.36 billion, a P/E ratio of 116.41, a PEG ratio of 3.52 and a beta of 0.35. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.89 and a current ratio of 2.17. The stock has a 50-day moving average price of $43.21 and a two-hundred day moving average price of $43.72. Qiagen has a 52-week low of $39.03 and a 52-week high of $47.44.

Qiagen Company Profile

(Get Free Report

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.

Featured Articles

Analyst Recommendations for Qiagen (NYSE:QGEN)

Should you invest $1,000 in Qiagen right now?

Before you consider Qiagen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Qiagen wasn't on the list.

While Qiagen currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Broadcom Hits $1 Trillion – Can This AI Powerhouse Go Higher?
SoundHound Stock Explodes Again – Is a Major Breakout Coming?
How Fintech Strategy at FinWise Bancorp and CEO Vision Are Driving 78% Gains

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines